The process of transitioning a fermentation or bioprocess from laboratory scale to pilot and commercial production volumes, requiring optimization of mass transfer, mixing, heat removal, and other parameters that change with vessel size.

What category does Scale-Up belong to?

Scale-Up is a fermentation concept in synthetic biology and synbio technology.

Scale-Up — Synthetic Biology Glossary

Scale-up is one of the most challenging and risk-prone phases in bringing a synthetic biology product to market. Performance that is achieved in small-scale laboratory bioreactors (typically 1 to 10 liters) frequently does not translate directly to pilot (100 to 1,000 liters) or production scale (10,000 to 200,000 liters). Key parameters that change with scale include oxygen transfer rates, mixing efficiency, heat removal capacity, and the uniformity of environmental conditions throughout the vessel. These physical differences can profoundly affect cell growth, metabolism, and product formation.

The synthetic biology industry has experienced numerous scale-up challenges. Amyris, one of the sector's pioneers, spent years and hundreds of millions of dollars optimizing the scale-up of its farnesene production process before achieving commercial viability. Bolt Threads encountered scale-up difficulties with its spider silk protein production. These experiences have informed a more cautious and systematic approach to scale-up across the industry, with companies investing in intermediate-scale piloting and computational fluid dynamics modeling to de-risk the transition to commercial volumes.

CDMOs (contract development and manufacturing organizations) play a critical role in helping synthetic biology companies navigate scale-up without building their own production facilities. Organizations like National Resilience, Ajinomoto Bio-Pharma, and Samsung Biologics offer contract fermentation and bioprocessing services at various scales. Ginkgo Bioworks provides both strain engineering and connections to manufacturing partners through its network. The availability of contract manufacturing capacity has become a strategic consideration for the synthetic biology industry, as the capital requirements for building dedicated production facilities can exceed hundreds of millions of dollars.